Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women
Autore:
Anderson, PW; Cox, DA; Sashegyi, A; Paul, S; Silfen, SL; Walsh, BW;
Indirizzi:
Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USAEli Lilly & Co Indianapolis IN USA 46285 Labs, Indianapolis, IN 46285 USA Brigham & Womens Hosp, Boston, MA 02115 USA Brigham & Womens Hosp Boston MA USA 02115 mens Hosp, Boston, MA 02115 USA
Titolo Testata:
MATURITAS
fascicolo: 1, volume: 39, anno: 2001,
pagine: 71 - 77
SICI:
0378-5122(20010725)39:1<71:EORAHR>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
CORONARY-ARTERY DISEASE; HEART-DISEASE; INTERVENTIONS PEPI; RISK FACTOR; LIPOPROTEIN; ESTROGEN; DENSITY; LIPIDS; APOLIPOPROTEINS; CHOLESTEROL;
Keywords:
raloxifene; hormone replacement therapy; serum atherogenicity; postmenopause;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
27
Recensione:
Indirizzi per estratti:
Indirizzo: Anderson, PW Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis,IN 46285 USA Eli Lilly & Co Indianapolis IN USA 46285 polis, IN 46285 USA
Citazione:
P.W. Anderson et al., "Effects of raloxifene and hormone replacement therapy on markers of serum atherogenicity in healthy postmenopausal women", MATURITAS, 39(1), 2001, pp. 71-77

Abstract

Objective: To determine the effect of raloxifene (RLX) and hormone replacement therapy HRT) on non-high density lipoprotein cholesterol (non-HDL-C) levels and the apolipoprotein-B/apolipoprotein-Al (apo-B/apo-Al) concentration ratio, markers of serum atherogenicity, in postmenopausal women. Methods: Three hundred and ninety healthy postmenopausal women aged 45-72 years were enrolled in a double-blind, randomized, placebo -controlled, parallel trial at eight outpatient sites in the United States. Women were randomly assigned to receive continuous combined HRT (0.625 mg/day conjugated equine estrogen and 2.5 mg/day medroxyprogesterone acetate), 60 or 120 mg/day raloxifene, or placebo for 6 months. Serum concentrations of non-HDL cholesterol and the apo-B/apo-Al concentration ratio were measured in serum samples obtained at baseline and at 6 months of treatment. Results: At 6 months, non-HDL-C and apo-B/apo-Al were significantly reduced by 60 mg/day RLX (10 and 11 %, respectively), 120 mg/day RLX (9 and 12%, respectively) and HRT (10 and 12%, respectively), compared with placebo. The effect of all treatments to lower non-HDL-C and apo-B/apo-Al was greatest in women with hypercholesterolemia (total-C > 240 mg/dl) at baseline. Among women with undesirable ( >160 mg/dl) non-HDL cholesterol at baseline, RLX and HRT lowered the percentage of these women remaining above this threshold after 6 months (placebo,89%; 60 mg/day RLX, 61%; 120 mg/day RLX, 74%; HRT, 58%). Similar results were observed for women with high (> 190 mg/dl) non-HDL cholesterol at baseline. Conclusion: In healthy postmenopausal women, RLX and HRT lower serum non-HDL-C and apo-B/apo-Al, indicators of serum atherogenicity, to a similarextent. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/03/20 alle ore 09:21:59